Novoste Outlines Plan To Weather Coming Flood Of Drug-Coated Stents
This article was originally published in The Gray Sheet
Executive Summary
Novoste will acquire several new vascular intervention products to sustain its sales force in 2003 and 2004, when new drug-coated stents are expected to quell demand for the company's Beta-Cath coronary brachytherapy system, the firm reported Jan. 10 at the JP Morgan Healthcare Conference in San Francisco